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 Abstract:  In January 2013, the international recommen-
dations of the KDIGO (for  “ Kidney Disease: Improving 
Global Outcomes ” ) to define chronic kidney disease 
(CKD) and classify patients in CKD stages have been pub-
lished. In this opinion article, we will review and discuss 
the most important guidelines proposed about CKD stag-
ing and glomerular filtration rate (GFR) estimating. In 
particular, we question the choice of fixed knot values 
at 60 mL/min/1.73 m ² to define CKD. We also question 
the strategies proposed to measure and use cystatin C 
results. 
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 Introduction 
 Assessment of kidney function is one of the most fre-
quent common practices in medicine. There are several 
ways to assess kidney function but one of the most fre-
quently used is certainly to measure or estimate glomer-
ular filtration rate (GFR). Measurement of GFR (e.g., by 
iohexol clearance) is relatively laborious even if we think 
the difficulties and costs have been systematically over-
estimated in recent scientific literature [ 1 ,  2 ]. Therefore, 
estimating GFR from biomarkers is still recommended 
and used in clinical practice. Nephrologists rely on the 
international recommendations of the Kidney Disease: 
Improving Global Outcomes (KDIGO) to define chronic 
kidney disease (CKD) and classify patients [ 3 ]. A new 
issue of these guidelines has been published in January 
2013. In this opinion article, we will discuss and question 
several recommendations in the field of GFR estimation, 
underlining the points of special interest for the clinical 
laboratory. 
 Definition of CKD 
 In order to define CKD, the KDIGO guidelines use the fol-
lowing criteria: albuminuria, urine sediment electrolytes 
abnormalities, histological abnormalities, and history of 
kidney transplantation. Regarding estimated GFR (eGFR), 
CKD is defined by eGFR < 60 mL/min/1.73 m ² without any 
distinction of age. This recommendation is not graded 
[ 3 ]. However, other experts in the field have challenged 
this approach to CKD definition [ 4 – 6 ]. Indeed, renal 
physiologists know that GFR physiologically decreases 
with aging. There are strong arguments showing that 
measured GFR (mGFR) in healthy older subjects may 
be  < 60 mL/min/1.73 m ² [ 4 ,  7 ,  8 ]. Omitting this physiologi-
cal data will lead to overestimation of CKD prevalence in 
the general population, and especially in the elderly [ 9 ]. 
In those patients, the level of GFR is usually lower than in 
young people. A lower GFR value may without doubt be 
the reason for a higher susceptibly of acute kidney injury 
or future progress to CKD. We believe, however, that this 
is not a reason to call these subjects  “ patients ” or  “ dis-
eased ” . Also, and maybe more importantly for the neph-
rologist, a 30-year-old patient with a GFR of 65 mL/min/
1.73 m ² could be considered healthy although his GFR 
value is well below the percentile 10 of the normal GFR in 
this age range. We think that the CKD definition proposed 
by the KDIGO leads to an overestimation of CKD preva-
lence in the older people and a potentially underestima-
tion of disease prevalence in young people [ 4 ]. We believe 
that the  “ variable ” age must be taken into account in the 
CKD definition. 
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 Staging CKD 
 The goal of the KDIGO guidelines is to propose inter-
national harmonization of CKD definition and staging 
which is undoubtedly a great advantage. The guide-
lines proposed to classify CKD by cause, albuminuria 
category and GFR category. In this paragraph, we will 
focus on the categorization of GFR. Six categories (G1 to 
G5, with G3 split in G3a and G3b) are proposed accord-
ing to GFR levels ( Table 1 ) [ 3 ]. The KDIGO underlines the 
fact that neither category G1 nor G2 can be considered as 
 “ disease ” if there is no evidence of other kidney damage. 
However, even in the context of albuminuria or of single 
kidney (post nephrectomy), we think the usefulness and 
relevance of two different stages (G1 vs. G2) is clinically 
questionable. For clinicians following these types of 
nephrologic patients, what is the interest of knowing the 
patient to be in G1 or G2? Moreover, we think that defin-
ing stage 1 as GFR > 90 mL/min/1.73 m ² does not allow the 
consideration of important physiological concepts like 
hyperfiltration in obese and diabetic patients (GFR > 120 
mL/min/1.73 m ² ) [ 2 ,  10 ]. These criticisms must also be 
understood with our prior proposition to adapt normal 
GFR values to age. 
 We would also like to discuss the splitting of G3 in 
G3a (GFR > 45 mL/min/1.73 m ² ) and G3b (GFR < 45 mL/min/
1.73 m ² ). Considering a cut-off at 45 mL/min/1.73 m ² could 
be important. Indeed, authors have shown with GFR 
measured by a reference method that CKD-related com-
plications (anemia, acidosis  … ) begin around 45 mL/min/
1.73 m ² [ 11 ]. Regarding our concern about normal GFR 
values in the elderly, we don ’ t question that an elderly 
subject with a GFR < 45 mL/min/1.73 m ² effectively suffers 
from CKD [ 4 ]. However, we make the difference between 
defining a new cut-off for stage 3 at 45 mL/min/1.73 m ² 
instead of 60 mL/min/1.73 m ² and splitting stage 3 into 3a 
 Table 1   Chronic kidney disease classification. 
 GFR category  GFR, mL/min/1.73 m ²  Term 
 G1  90  Normal or high 
 G2  60 – 89  Mildly decreased 
 G3a  45 – 59  Mildly to moderately 
decreased 
 G3b  30 – 44  Moderately to 
severely decreased 
 G4  15 – 29  Severely decreased 
 G5  < 15  Kidney failure 
 CKD, chronic kidney disease; GFR, glomerular filtration rate. In the 
absence of evidence of kidney damage, neither GFR category G1 nor 
G2 fulfill the criteria for CKD. 
and 3b. Splitting the stage 3 necessarily implies that diag-
nosing and differentiating the  “ subgroups ” is possible. 
In this context, the range of 15 mL/min/1.73 m ² (stage G3b 
is defined as 30 – 45 and stage 3a 45 – 60 mL/min/1.73 m ² ) 
could be too tight to be of clinical use. Indeed, we think there 
is little chance that any equation may correctly estimate 
GFR (and thus staging) with a precision of  < 15 mL/min/
1.73 m ² . In the recent study published by the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) 
consortium, the precision of the GFR equations (defined 
as IQR of the difference between measured and estimated 
GFR) was 10, 11, and 8 mL/min/1.73 m ² in subjects with 
eGFR < 60 mL/min/1.73 m ² for the CKD-EPI creatinine, the 
CKD-EPI cystatin C, and the combined (creatinine and cys-
tatin) CKD-EPI equation, respectively [ 12 ]. Thus this preci-
sion of approximately 10 mL/min/1.73 m ² is probably too 
close to the difference of 15 mL/min/1.73 m ² allowing stage 
3a to be separated from stage 3b. In other words, it is not 
useful to split stages in subgroups if there is no method 
that accurately differentiates these subgroups. 
 Evaluation of GFR: creatinine and 
creatinine-based equations 
 GFR estimation is one of the main criterions to define CKD. 
The question  “ how to evaluate or estimate GFR ” is thus 
crucial. In the last decades, several new equations have 
been proposed. These equations have been developed 
from  “ renal ” biomarkers like the classical  “ serum creati-
nine ” as well as the promising  “ cystatin C ” . We are now 
discussing the main guidelines proposed in the chapter 
 “ evaluation of GFR ” . We briefly remind the nomencla-
ture of the KDIGO: level 1 is a recommendation and level 
2 is a suggestion. Gradation from A to D is correspond-
ing to the quality of evidence, from high to very low 
quality. 
 Guideline 1.4.3.1:  “ We recommend using serum creatinine and a 
GFR estimating equation for initial assessment. ” 
 This guideline is the only one with such a high level of 
evidence (1A). Using serum creatinine for initial assess-
ment is, of course, not questionable. Using system-
atically creatinine-based equations is yet less evident 
(see below). 
 Guideline 1.4.3.2:  “ We suggest using additional tests (such as cys-
tatin C or a clearance measurement) for confirmatory testing in 
specific circumstances when eGFR based on serum creatinine is 
less accurate. ” 
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 The level of evidence for this recommendation is low 
(2B). Also, this guideline remains relatively vague, as cir-
cumstances where eGFR based on serum creatinine is 
less accurate are not clearly specified [ 3 ]. Nevertheless, 
knowing the intimate relationship between serum cre-
atinine and muscular mass, we would hypothesize using 
additional testing in subjects with abnormal muscular 
mass. More importantly, the recommendation is not spe-
cific about the choice of such  “ additional tests ” . Cystatin 
C is a GFR biomarker known and studied from 1985 [ 13 ]. 
Cystatin C is freely filtrated by the glomerulus and then 
entirely reabsorbed by the proximal tubules, where it is 
almost entirely catabolized [ 14 ,  15 ]. The advantage of cys-
tatin C over serum creatinine is often presented as the lack 
of dependency on muscular mass [ 16 ], even if this point 
has been challenged [ 17 – 19 ]. We will discuss the interest 
of cystatin C further. Additionally, the guidelines propose 
to use  “ clearance measurement ” without any additional 
precision. This point is a source of frustration as several 
different types of clearances, including creatinine clear-
ances, could be grouped in the words  “ clearance meas-
urement ” [ 1 ]. We think the choice of the additional testing 
will strongly depend on the reason why we need GFR. 
In situations where a degree of precision is needed or in 
patients where creatinine-based equations are suspected 
to be inaccurate, there is little interest to estimate GFR 
with another biomarker or creatinine clearance and we 
recommend using a reference method for measuring GFR. 
We believe that giving the same weight to cystatin C meas-
urement as to the GFR reference method for confirmatory 
testing is misleading. Regarding our actual knowledge, it 
could be considered as a  “ positive ” exaggeration of the 
potential role of cystatin C. 
 Guideline 1.4.3.3:  “ We recommend that clinicians use a GFR esti-
mating equation to derive GFR from serum creatinine rather than 
relying on the serum creatinine concentration alone and under-
stand clinical settings in which creatinine-based estimation is less 
accurate. ” 
 One reason to recommend equations is that the same 
serum creatinine concentration does not mean the same 
in terms of GFR if gender, age and ethnicity are consid-
ered [ 20 – 23 ]. However, this recommendation totally 
ignores the interesting publications by Pottel et al. who 
proposed considering only serum creatinine and to adapt 
the results to different normal reference values in those 
different populations [ 24 ,  25 ]. Also important, we have 
no proof that using creatinine-based equations is better 
than using serum creatinine (or the inverse of serum cre-
atinine) to estimate the GFR slope in the follow-up of our 
patients [ 2 ,  26 ]. 
 Guidelines 1.4.3.4:  “ We recommend that clinical laboratories 
should measure serum creatinine using a specific assay with cali-
bration traceable to the international standard reference materials 
and minimal bias compared to isotope-dilution mass spectrometry 
(IDMS) reference methodology. ” 
 This recommendation for clinical laboratories is clear and 
the level of evidence is high (1B). The literature is abun-
dant and a lot of authors have well described severe con-
sequences of non-calibration on eGFR results [ 27 ,  28 ]. At 
this point, we would like to underline the fact that both 
the Modified Diet in Renal Disease (MDRD) study and 
CKD-EPI equations, which is favored by the KDIGO (see 
below), have been developed from samples measured 
mostly with the Jaffe assay not directly standardized to 
IDMS [ 29 – 31 ]. Traceability has been obtained indirectly 
and a posteriori [ 32 ,  33 ]. From a  “ Clinical Chemistry ” per-
spective, we believe the way this standardization has been 
obtained in those studies is far from ideal [ 34 ,  35 ]. 
 Moreover, the precision (i.e., the random error) of GFR 
equations, will strongly depend on the potential error of 
the main variable included, i.e., serum creatinine. Its role 
is particularly important bearing in mind that the remain-
ing variables included in GFR equations (age, gender and 
ethnicity) have a potentially smaller risk of error. Due to 
the exponential relationship between serum creatinine 
and GFR [ 35 ], the erroneous effect is particularly present 
in the estimation of high GFR (low creatinine levels). From 
the laboratory ’ s point of view, we are thus disappointed by 
the absence of recommendation regarding the better pre-
cision of the enzymatic assays in comparison to the Jaffe 
assay [ 36 ,  37 ]. The preference of the enzymatic method is 
relevant for the precision of the creatinine measurement 
and thus for the precision of the equations [ 37 – 39 ]. More-
over, we have to keep in mind that a French independent 
study has recently proven that enzymatic assays are truly 
IDMS traceable [ 36 ]. 
 Guidelines 1.4.3.4 (followed):  “ We recommend that clinical labo-
ratories should report eGFR in addition to the serum creatinine 
concentration in adults and specify the equation used whenever 
reporting eGFR. ” 
 As nephrologist, we globally agree about this recommen-
dation but clinical laboratories ought to be more careful 
because their responsibility is engaged and very high. 
Clinical Chemists should remind clinicians on a regular 
basis that equations are and remain an estimation, an 
approximation. A very interesting alternative proposed 
by Bjork et al. is to show GFR results as a probability for 
patients being at stage G1, G2 or G3 instead of showing a 
 “ pure ” result [ 40 ]. 
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 Guidelines 1.4.3.4 (followed):  “ We recommend that clinical labo-
ratories report eGFR in adults using the 2009 CKD-EPI creatinine 
equation. An alternative creatinine-based GFR estimating equa-
tion is acceptable if it has been shown to improve accuracy of GFR 
estimates compared to the 2009 CKD-EPI creatinine equation ” . 
 The recent guidelines have logically been largely influ-
enced by the studies from the CKD-EPI consortium [ 3 ]: 
indeed, the leaders of the CKD-EPI consortium have par-
ticipated in the redaction of the KDIGO recommendations, 
the  “ Evidence Review Team ” was localized in Boston 
(where the CKD-EPI leaders work), and the equations dis-
cussed in the KDIGO are those published by the consor-
tium [ 12 ,  30 ,  41 ]. However, it is unfortunate that the authors 
of the guidelines have omitted to discuss (and even to cite 
in the bibliography) other creatinine- or cystatin C-based 
equations proposed by other authors and developed with 
an accurate methodology. For example, we can cite the 
quadratic equations from the  “ Mayo clinic ” [ 42 ,  43 ], the 
Lund-Malm ö [ 44 ] and the Berlin Initiative Study (BIS) 
equations [ 45 ]. We acknowledge that the data provided 
and published by the consortium are impressive notably 
in terms of sample. However, because nobody (and no 
study) is perfect, we have also to underline some limita-
tions of the main studies from the CKD-EPI consortium. 
The CKD-EPI equation is now favored by the CKD-EPI 
leaders and by the KDIGO guidelines. They thus recom-
mend abandoning the MDRD study equation [ 3 ,  30 ]. They 
assert that this equation performs better than the prior 
MDRD study equation, which has been shown to under-
estimate mGFR in high or normal GFR levels, leading to 
an overestimation of CKD prevalence. Therefore, recom-
mending the CKD-EPI equation at the population level 
(i.e., in epidemiologic studies) makes sense as its bias has 
been shown to be better in healthy subjects [ 30 ,  46 ]. At the 
individual level, this assertion is however questionable as 
the random error of the equation (i.e., the precision) is not 
shown to be better. In fact, considering the patient and the 
daily practice, the superiority of the CKD-EPI equation is 
solely evident and relevant in G1 subjects ( > 90 mL/min/
1.73 m ² ), and not in the  “ key zone ” around 60 mL/min/
1.73 m ² [ 30 ,  47 – 52 ]. We question thus the role of the CKD-EPI 
equation as the  “ point of reference ” to potentially validate 
other equations. 
 Guidelines 1.4.3.4 (followed):  “ We recommend that serum cre-
atinine concentration be reported and rounded to the nearest 
whole number when expressed as standard international units 
( µ mol/L) and rounded to the nearest 100th of a whole number 
when expressed as conventional units (mg/dL). We recommend 
that eGFR should be reported and rounded to the nearest whole 
number and relative to a body surface area of 1.73 m ² in adults 
using the units mL/min/1.73 m ² . ” 
 With regard to the important issue of harmonization 
and standardization, we believe that it is time to favor 
standard international units. We fully agree with the pro-
posed  “ rounding ” as expressions like  “ 100.56 mL/min/
1.73 m ² ” are cumbersome and make no sense both from a 
clinical and biological point of view. 
 Guidelines 1.4.3.4 (followed):  “ We recommend eGFR levels  < 60 
mL/min/1.73 m ² should be reported as decreased. ” 
 Regarding the last part of the recommendation, we wonder 
why the guidelines recommend five CKD stages but ask 
the laboratory to simply report  “ decreased ” without indi-
cating a stage. It could be interpreted as a  “ reductio ad 
absurdum ” of the complexity of the staging (five stages 
with one split stage), in particular for the general phy-
sician. Moreover, in  “ the MDRD area ” , several authors 
proposed that laboratories should display GFR results as 
 “ > 60 mL/min/1.73 m ² ” without the absolute value because 
imprecision of the creatinine measurement results in a 
lower precision of the estimate for high GFR levels [ 38 , 
 39 ]. This important issue for the clinical chemists has not 
been mentioned in the new guidelines. Even if the preci-
sion could theoretically be better with the CKD-EPI equa-
tion (simply because the exponent applied to creatinine in 
the high GFR levels is lower than in the MDRD equation) 
this improvement is not proven in clinical studies [ 51 ]. 
 Evaluation of GFR: cystatin C 
 It is beyond the scope of this article to discuss all the poten-
tial or theoretical advantages, as well as the limitations of 
cystatin C as a marker for GFR estimation. Several review 
articles have been published on the topic, including in this 
journal [ 53 – 55 ]. One of the main limitation of cystatin C 
and cystatin C-based equations was the lack of standardi-
zation between assays leading to potential discrepancies 
similar to the ones observed in creatinine-based equations 
[ 56 – 59 ]. Standardization is however available since 2011 
and this is considerable improvement for the topic  “ esti-
mating GFR with cystatin C-based equations ” [ 60 ]. This 
improvement is, however, not synonymous of  “ perfec-
tion ” and, e.g., this new standardization is inferior to the 
IDMS-traceability observed for creatinine measurements. 
In other words, we have now a standardized calibrator, 
but we are still waiting for a  “ true ” reference method to 
measure cystatin C, i.e., with mass spectrometry. Regard-
less of the limitations of the standardization, this process 
is an important improvement and necessary milestone 
for the implementation of cystatin C-based equations. 
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Equations based on standardized cystatin C (CKD-EPI cys-
tatin C) or cystatin C and creatinine (combined CKD-EPI 
equation) have been proposed by the CKD-EPI consortium 
in 2012 [ 12 ]. The way of obtaining cystatin C calibration 
is, however, not unquestionable. The calibration has been 
done a posteriori (from samples frozen for more than 5 
years) and indirectly. Cystatin C results may differ accord-
ing to year of sampling as calibration of the Siemens assay 
has changed over time [ 12 ,  58 ]. 
 The main conclusion of the CKD-EPI study with cys-
tatin C-based equations is the superior performance of 
the combined equation over the CKD-EPI creatinine and 
CKD-EPI cystatin C equations. Interestingly, the better per-
formance was obtained by an improvement in precision of 
the equation. In participants whose estimated GFR based 
on CKD-EPI creatinine was 45 – 74 mL/min/1.73 m ² , the 
combined equation improved the classification of meas-
ured GFR as either less or  > 60 L/min/1.73 m ² (net reclas-
sification index of 19.4%) and correctly reclassified 16.9% 
of those with an estimated GFR of 45 – 59 mL/min/1.73 m ² 
as in fact having a GFR of  > 60 mL/min/1.73 m ² [ 12 ]. From 
this observation, the guidelines 1.4.3.5 suggest the follow-
ing strategy: 
 Guidelines 1.4.3.5:  “ We suggest measuring cystatin C in adults 
with eGFRcreat 45 – 59 mL/min/1.73 m ² who do not have markers 
of kidney damage if confirmation of CKD is required: If eGFRcys/
eGFRcreat-cys is also  < 60 mL/min/1.73 m ² , the diagnosis of CKD 
is confirmed; If eGFRcys/eGFRcreat-cys is  > 60 mL/min/1.73 m ² , 
the diagnosis of CKD is not confirmed. 
 Such a strategy implies that cystatin C should be measured 
in a lot of patients in the general population (and not in 
specific ones). It is clearly a suggestion more than a recom-
mendation because such a strategy is based on few studies. 
Clearly, at this point, other studies are necessary to confirm 
the clinical relevance, but also the cost-effectiveness, of 
such a strategy to screen CKD in the general, but also in 
more specific populations [ 61 ]. 
 Other guidelines about the use of cystatin C remain 
unspecific and relatively vague. For instance, for the cli-
nician, it remains still unclear which of the two CKD-EPI 
equations (combined or based only on cystatin C) should 
be used when. This important question needs future 
investigations. 
 Conclusions 
 In this opinion paper, we take the liberty to criticize the 
new KDIGO guidelines. A minimum of harmonization is 
indispensable for a classification, and probably at a given 
moment, arbitrary choices have to be made. Our main 
critics are finally about the arguments frequently proposed 
to justify these guidelines: e.g., the unique cut-off value 
of  “ normal GFR ” at 60 mL/min/1.73 m ² , the choice of the 
CKD-EPI creatinine equation instead of the MDRD, or the 
preference for cystatin C instead of creatinine-based equa-
tions. Indeed, most of these arguments are epidemiological 
ones: eGFR < 60 mL/min/1.73 m ² is associated with higher 
mortality, CKD-EPI better predicts mortality than MDRD, 
and cystatin C also better predicts cardiovascular outcomes 
than creatinine [ 62 – 65 ]. These arguments are probably valid 
from both an epidemiological and predictive point of view 
but we believe that in clinical practice disease prediction 
for future population is not the primary role of the GFR esti-
mation equation. Non-GFR determinants potentially play 
an important role in the  “ prediction ” of the biomarkers and 
the statistics used seem to be of influence for such demon-
strations (high risk of collinearity) [ 4 ,  66 ,  67 ]. It may be time 
for clinicians who are the ones taking care of patients to 
take their part in the debate and to propose alternatives. 
 We acknowledge that we might have been too severe 
in several occasions in this opinion paper. We know that 
guidelines elaboration has requested a lot of work and 
recommendations are the results of a lot of debate. It is 
almost always easier to destruct than to build. On the 
other side, guidelines are not carved in stone and discus-
sion and debate are nutriments of science. 
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